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A prospective randomized study for prevention of postrenal
transplantation bone loss.
Background. We aimed to investigate different treatment
drugs for the prevention of post-transplant bone loss.
Methods. Sixty adult male recent renal transplant recipients
were enrolled into the study. Patients were randomized into
4 groups: group I received daily alfacalcidol 0.5 lg PO; group
II received oral alendronate 5 mg/day; group III received in-
tranasal salmon calcitonin 200 IU every other day; and group
IV was considered a control group. Every patient was supple-
mented with daily 500 mg oral calcium carbonate. Parameters of
bone metabolism were measured before and at 12 months after
starting treatment. Bone mineral density (BMD) was measured
by (DEXA) at lumber spine, femoral neck, and forearm before
and after treatment period.
Results. BMD was increased at lumber spine by 2.1%, 0.8%,
1.7%, by 1.8%, 0.6%, 1.6% at femoral neck, and by 3.2%, 1.9%,
2.6% at forearm in groups I, II, and III, respectively, while it de-
creased by 3.2%, 3.8%, and 1.8% at the same sites, respectively,
in control group (P = <0.05). iPTH level decreased significantly
in group I, while the decrease was insignificant in other groups
(P = 0.003). All other parameters were not statistically signifi-
cant between treatment groups. Apart from transient hypocal-
caemia in 3 patients in group II, and 2 patients in group III, no
other significant adverse effects were noted.
Conclusion. This study proves that early bone loss that oc-
curs during the first 12 months after renal transplantation could
be prevented by alfacalcidol, calcitonin, or alendronate. Among
the treatment groups, alfacalcidol significantly improved the hy-
perparathyroidism. All treatment drugs are safe and tolerable.
Despite the ability of renal transplantation (RTx) to
restore many of the excretory, metabolic, and hormonal
abnormalities of chronic renal failure and dialysis im-
plicated in the development of renal osteodystrophy,
osteoporosis remains a frequent and serious complica-
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tion affecting renal transplant recipients [1]. Short-term
studies of bone loss following RTx have indicated rapid
bone loss within the first 6 to 18 months after grafting [2].
Cross-sectional data suggest that beyond 3 years after
transplantation, the bone mineral density (BMD) does
not change or may increase slightly, but remains less than
normal population of reference values [3]. However, oth-
ers have suggested a continuous demineralization process
in long-term RTx recipients [4].
In renal transplant patients, in addition to known risk
factors for bone loss in healthy populations, other ab-
normalities could negatively affect the bone metabolism,
including the pretransplant renal osteodystrophy, persis-
tent hyperparathyroidism, and use of immunosuppres-
sive drugs [5, 6]. The role of glucocorticoid-induced
osteoporosis (OP) is well documented in many series [7],
and there is evidence that cyclosporine A (CsA) causes
increase bone resorption due to increased osteoclast ac-
tivity [9].
Prevention or treatment of OP has obtained mixed re-
sults [9, 10]. Vitamin D analogues and calcium have ben-
eficial effects in the prevention of glucocorticoid-induced
bone loss [11, 12]. The antiresorptive properties of calci-
tonin have been used to treat high turnover, as well as
glucocorticoid-induced OP in humans, but with variable
results [13–15]. Biphosphonates, which inhibit bone re-
sorption, have been shown in many studies [14, 16] to
ameliorate the glucocorticoid-induced bone loss.
We aimed to investigate the efficacy and safety of dif-
ferent treatment drugs, alfacalcidol, alendronate, and cal-
citonin in the prevention of bone loss in renal transplant
recipients in a prospective study.
METHODS
Patients
This was a prospective open, randomized study. Sixty
patients who underwent live-donor RTx in our institution
entered the study after obtaining an informed consent
according to local Institutional Review Board, Ministry of
Health. The characteristics of the patients are outlined in
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Table 1. Inclusion criteria were male patients aged more
than 20 years old, not diabetic, did not receive steroids
before transplantation, and were on hemodialysis for not
more than 2 years. We excluded patients with impaired
graft function (i.e., serum creatinine >2 mg/dL), presence
of previous fractures, and presence of hypogonadism or
suprarenal gland diseases.
Immunosuppression
All the patients received 500 mg methylprednisolone
before and on the day of transplantation, and then oral
prednisolone was given 3.5 mg/kg/day for 2 days, then
1.5 mg/kg/day for 5 days, and then was tapered until it
reached 0.15 mg/kg/day from the ninth month thereafter.
CsA was given 2 days before transplantation at a dose
of 8/mg/kg/day in 2 divided doses, and then the dosages
were adjusted to keep the whole blood trough level be-
tween 200 and 300 ng/mL during the first 2 months, and
then between 100 and 150 ng/mL thereafter using mon-
oclonal antibodies (TDx, Abbott Diagnostics, IL, USA).
All acute rejection episodes were treated with 500 mg
methylprednisolone pulses for 5 days.
Study design
Upon enrollment, patients were randomly assigned
for a 1-year single-blind trial. Patients were allocated
randomly to 1 of the 4 treatment groups using a computer-
generated sequence. Information regarding the random-
ized treatment was concealed in sequentially numbered,
sealed opaque envelopes. These were opened in the ab-
sence of the patients immediately after obtaining in-
formed written consent for participation in the study. The
participant physicians were necessarily aware of the ran-
domized treatment in all cases, but patients and members
of staff in the various clinical laboratories were blinded to
this information. Patients were randomized into 4 groups,
either to receive alfacalcidol 0.5 mg/day PO (group I) or
to receive alendronate 5 mg/day PO (group II), or to re-
ceive calcitonin 100 lL intranasally every other day and
were stopped for 1 month every 3 months (group III),
and group VI did not receive additional drugs and served
as control group. All patients received 500 mg/day PO
supplemented calcium carbonate. Treatment was started
after graft function was obtained, but not later than 1
week after transplantation. If severe hypercalcemia oc-
curred (adjusted Ca, 11 mg/L), the study medication had
to be interrupted and eventually stopped definitively. If
hypocalcemia occurred, calcium supplementation was in-
creased. The treatment drugs started within the first week
after transplantation at a mean interval of 3.3 ± 1.8 days
with no significant difference between groups. During the
observation period the patients did not receive fluoride,
vitamin D, or any hormonal therapy.
Laboratory analysis
Routine laboratory test, including renal function tests,
albumin, and CsA whole blood trough level were mea-
sured for all patients. Biochemical analyses were per-
formed on serum/urine samples obtained in the morning
after fasting and on 24-hour urine collections at baseline,
at 3, 6, and 12 months. Biochemical markers of bone re-
sorption and formation included serum calcium and phos-
phorus, alkaline phosphatase, 24-hour urinary excretion
of calcium, serum intact parathyroid hormone (iPTH),
the normal value range of which is 1.0 to 6.5 pmol/L,
using an immunoradiometric assay (Allergo; Nichols
Institute, San Juan Capistrano, CA, USA); serum os-
teocalcin using radioimmunoassay (Cis kits, Marseille,
France) with interassay coefficient of variation was <3%;
and urinary deoxypridinoline excretion using immuno-
radiometric assay (ACS Bayer, Mannheim, Germany)
with interassay coefficient of variation was <6%. All
laboratory tests were measured before treatment and at
12 months after treatment.
Bone mineral density (BMD)
BMD of lumber spine, femoral neck, and forearm was
determined by dual energy x-ray absorbiometry (DEXA)
using scanner (Lunar Corp., Madison, WI, USA). Results
were compared with values of an age- and sex-matched
reference populations (Z score), and with value of sex-
matched peak bone mass of young control population (T
score). The reference populations were of the same race.
The radiology department provided quality control and
phantom cross-calibration for the DEXA measurements.
The calibration factor from the quality control provided
standardization of the results among the 3 clinical sites.
The coefficient of variation for femoral neck was 2.1%,
1.6% for L1 to L4, and 1.8% for forearm. All data were
evaluated before and at 12 months after treatment.
Adverse effects
All patients completed 1 year of the trial. All clinical
and laboratory side effects that occurred during the study
were recorded, and their causes were evaluated.
Statistical analysis
Statistical analysis was done using IBM-compatible
SPSS package version 10 (SPSS Corp., Chicago, IL,
USA). Analyses were performed according to the
intention-to-treat principle. Assuming a reduction of the
estimated bone loss from 5.4% to 2.5% during the first 12
months after transplantation and a power of 0.80 and of
0.05, it was calculated that at least 15 patients should be
included in each group. Comparison of the basal values
was done by the chi-square test for qualitative variables
and by nonparametric tests, Kruskal-Wallis one-way anal-
ysis of variance (ANOVA) for quantitative variables.
El-Agroudy et al: Prevention of postrenal transplantation bone loss 2041
Table 1. Patient characteristics of the four groups
Alfacalcidol group Alendronate group Calcitonin group Control group
(N = 15) (N = 15) (N = 15) (N = 15) P value
Age years (M ± SD) 31.4 ± 10.1 31.6 ± 8.6 32.3 ± 7.9 31.6 ± 10.1 0.99
(Range) 18–50 18–48 22–43 19–58
Time on dialysis months 10.8 ± 5.4 10.5 ± 5.6 12.6 ± 6.8 12.1 ± 6.3 0.85
Acute rejection/patient 1.2 ± 1.1 1.2 ± 1.0 1.3 ± 1.1 1.2 ± 1.1 0.54
Cumulative steroid at 1 year g
(M ± SD) 15.9 ± 5.4 12.7 ± 2.6 14.3 ± 3.7 13.3 ± 2.6 0.08
(Range) 10–30 7.5–15 10–20 7.5–17.5
Cumulative CsA doses at 1 year mg/day 147 ± 54 154 ± 29 149 ± 50 148 ± 51 0.76
Body weight kg 69.5 ± 15.1 72.6 ± 16.4 76.0 ± 8.5 75.3 ± 13.6 0.59
Changes within the groups after end of the study period
were analyzed by Wilcoxon matched-pairs signed-rank
and Mann-Whitney U test. ANOVA with corresponding
baseline values and therapy as covariates was performed
to test for differences of changes between the treatment
groups. Results were given as mean ± standard deviation
unless otherwise indicated. P values < 0.05 were consid-
ered significant.
RESULTS
Patient characteristics
A summary of baseline patient characteristics is shown
in Table 1. A majority of patients received calcium sup-
plementation before transplantation. The main causes of
end-stage renal disease were chronic interstitial nephritis
in 23 patients, nephrosclerosis in 10 patients, glomeru-
lonephritis in 5 patients, and hereditary nephritis in 4
patients. There were no episodes of acute rejection or
delayed graft function in any of the patients enrolled into
the study before starting treatment. No bony symptoms
or fractures were registered in any group during the ob-
servation period.
In terms of post-transplantation factors, there were no
significant differences in the main cumulative steroids
doses after 1 year of follow-up for all groups (P = 0.08).
The time of exposure to corticosteroids (date of trans-
plantation) until the starting date of the study was not dif-
ferent between the treatment groups and control group.
During the study period, the prednisolone dosages were
further reduced in all groups, and this reduction was not
statistically significant between all groups. The incidence
of acute rejections after starting the study was also simi-
lar in both groups (21%, 24%, 23%, and 23% in groups I,
II, III, and IV, respectively). Rejections in most patients
were treated successfully with intravenous methylpred-
nisolone.
Biochemical parameters
Detailed biochemical characteristics are listed in
Table 2. Baseline biochemical investigations were per-
formed at the time of entry of the study. There were no sta-
tistically significant differences seen between the groups.
A high proportion of patients in all groups (73%, 66%,
73%, 66% in groups I, II, III, IV, respectively) demon-
strated elevated iPTH levels at baseline. In contrast, the
baseline osteocalcin values were below the lower limits
of normal in 42 patients (70%) with nonstatistical dif-
ference between groups (P = 0.14). Values of alkaline
phosphates were above upper limits of normal values in
more than 60% of patients. Average serum calcium levels
were found in most of the patients in all groups; however,
the values were near the lower limit of normal in 35 pa-
tients (64%). The statistical differences were not different
between groups (P = 0.36).
In case of serum creatinine values, although a trend
of gradual increase was observed throughout the study
period until the end of the study after 12 months, this dif-
ference did not reach statistical significance. To simplify
data presentation, only the initial and final results of all
variables are shown in Table 3.
Serum calcium values increased nonsignificantly in
groups II, III, and IV (P > 0.05), and this increase was
statistically significant in group I. There was a statisti-
cally significant difference between groups at the end of
the study (P = 0.001).
The results of the plasma measurements of the iPTH
are shown in Table 2. During therapy, iPTH decreased
significantly in the treatment groups without reaching
normal values. This reflects the ability of the prevention
therapy to partially control the secondary hypersecretion
of PTH. The iPTH values decreased significantly in group
I (P = 0.003) compared to treatment groups II and III,
as well as the control group (P > 0.05). However, this
significant decrease in iPTH was not matched with the
decrease in serum osteocalcin levels in group I, as well as
other treatment and control groups, as shown in Table 2.
During follow-up with prevention therapy, formation
markers showed no significant change in all patients.
Resorption markers were significantly high in the all
groups (Table 2). Urinary deoxypridinoline (DPD) de-
creased nonsignificantly in all groups at the end of the
study.
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Table 2. Metabolic parameters at baseline and after 12 month of treatment in all groups
Alfacalcidol Alendronate Calcitonin Control
group (N = 15) group (N = 15) group (N = 15) group (N = 15) P value Normal
Baseline 12 months Baseline 12 months Baseline 12 months Baseline 12 months Pa Pb range
Serum creatinine 1.2 ± 0.3 1.4 ± 0.3 1.3 ± 0.4 1.3 ± 0.5 1.4 ± 0.4 1.4 ± 0.5 1.3 ± 0.3 1.3 ± 0.4 0.71 0.63 0.6–1.3
mg/dL
Serum calcium 8.7 ± 0.6 9.9 ± 0.4 8.6 ± 0.3 9.5 ± 0.4 8.7 ± 0.5 9.6 ± 0.4 8.6 ± 0.5 9.3 ± 0.3 0.69 0.001 8.6–10.6
mg/dL
Serum phosphorus 4.9 ± 0.9 3.2 ± 0.6 4.7 ± 0.9 3.3 ± 0.7 4.5 ± 0.9 3.6 ± 0.3 4.8 ± 0.8 3.5 ± 0.4 0.81 0.36 2.4–4.6
mg/dL
Alkaline 171 ± 50 90 ± 22c 151 ± 50 119 ± 30 147 ± 40 115 ± 26 131 ± 33 122 ± 31 0.15 0.01 60–120
phosphatase
IU/L
Serum albumin 3.8 ± 0.3 3.9 ± 0.4 3.8 ± 0.4 3.9 ± 0.6 3.9 ± 0.4 3.9 ± 0.3 3.9 ± 0.4 3.9 ± 0.4 0.45 0.97 3.2–4.2
g/dL
iPTH pg/mL 7.3 ± 2.6 2.8 ± 1.7c 7.8 ± 3.3 5.7 ± 3.1 6.4 ± 1.3 5.8 ± 1.5 6.3 ± 2.2 4.8 ± 2.7 0.33 0.003 1–6 pm/L
Serum osteocalcin 30.9 ± 14 27.6 ± 22 47.9 ± 25 26.5 ± 14 47.2 ± 19 41.0 ± 17 31.8 ± 25 22.5 ± 7 0.17 0.62 10–60
mg/dL
Deoxypyridinoline 80.8 ± 25 51.4 ± 44 74.9 ± 38 63.7 ± 32 55.4 ± 17 42.5 ± 37 74.4 ± 19 61.6 ± 39 0.43 0.71 20–55
mg/g urinary
creatinine
Urinary calcium 6.0 ± 6.8 3.8 ± 2.4 3.9 ± 4.0 3.2 ± 2.1 7.4 ± 8.0 2.3 ± 1.9 8.7 ± 6.8 4.4 ± 2.5 0.29 0.28 <7.5
mmol/day
aBetween groups at the entry of the study.
bBetween groups after 12 months.
cBetween the same group before and after the end of the study if significant.
Table 3. BMD at baseline and at the end of the study in all groups
Alfacalcidol Alendronate Calcitonin Control
group (N = 15) group (N = 15) group (N = 15) group (N = 15) P value
Baseline 12 months Baseline 12 months Baseline 12 months Baseline 12 months Pa Pb
BMD at lumber 1.1 ± 0.12 1.2 ± 0.11 1.1 ± 0.13 1.3 ± 0.33 1.0 ± 0.11 1.1 ± 0.23 1.1 ± 0.34 1.1 ± 0.30 0.48 0.44
spine g/cm2
BMD at lumber −1.3 ± 1.1 −1.1 ± 1.1 −1.4 ± 1.1 −1.2 ± 0.7 −1.1 ± 0.8 −1.0 ± 0.1 −1.0 ± 2.2 −1.3 ± 0.5 0.59 0.06
spine (SD
below normal)
BMD at lumber 85.6 ± 9 87.7 ± 6 84 ± 8 84.8 ± 7 82.1 ± 8 83.8 ± 9 81.3 ± 8 78.1 ± 5 0.46 0.04
spine (% of
normal BMD)
BMD at femoral 0.93 ± 0.1 1.0 ± 0.02 0.97 ± 0.1 1.1 ± 0.02 0.92 ± 0.1 1.0 ± 0.1 0.93 ± 0.1 0.91 ± 0.1 0.87 0.26
neck g/cm2
BMD at femoral −1.2 ± 1.0 −0.3 ± 0.2 −0.9 ± 1.3 −0.3 ± 0.4 −1.2 ± 0.6 −0.3 ± 0.5 −0.8 ± 1.5 −1.1 ± 0.7 0.88 0.36
neck (SD
below normal)
BMD at femoral 87.3 ± 9 89.1 ± 2 85.7 ± 12 86.3 ± 3 83.1 ± 4 84.7 ± 4 85.3 ± 12 81.5 ± 7 0.36 0.01
neck (% of
Normal BMD)
BMD at forearm 0.7 ± 0.12 1.3 ± 0.14 0.7 ± 0.01 1.0 ± 0.07 0.6 ± 0.11 1.0 ± 0.06 0.7 ± 0.12 0.7 ± 0.04 0.69 0.06
g/cm2
BMD at forearm −1.5 ± 0.9 −0.7 ± 0.1 −1.0 ± 0.6 −0.5 ± 0.3 −1.8 ± 1.4 −0.9 ± 1.1 −1.4 ± 1.1 −1.3 ± 0.4 0.40 0.05
(SD below
normal)
BMD at forearm 83.6 ± 9 86.8 ± 8 86.2 ± 5 88.1 ± 3 82.5 ± 6 85.1 ± 5 84.8 ± 9 83 ± 7 0.36 0.05
(% of normal
BMD)
aBetween groups at the entry of the study.
b Between groups after 12 months.
Bone mineral density (BMD)
Table 3 shows the values of BMD found in our renal
transplant patients after 1 year, and before the beginning
of the study. At baseline, a majority (45%) of patients
had BMD-defined osteopenia at lumber spine, 36% at
femoral neck of femur, and 65% at forearm, whereas a
smaller number of patients had BMD-defined osteoporo-
sis at these sites, respectively (11.4%, 13.3%, 5% at the
same sites, respectively). These differences were not sta-
tistically significant (P = 0.12).
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After 1 year of follow-up, BMD at lumber spine in-
creased by 2.1%, 0.8%, 1.7% in groups I, II, III, respec-
tively, while it decreased by 3.2% in the control group
(P = 0.04), while the increase was statistically significant
in group I compared to other treatment groups II and
III (P = 0.01) at this site. At forearm, the improvement
in BMD was also statistically significant in the treatment
groups compared to the control group (P = 0.05). At
the neck femur, the same trend of improvement was also
found in the treatment group compared to the control
group (P = 0.01); however, the increase was statistically
significant in group I compared to treatment groups II and
III (3.2%, 1.9%, 2.6% in groups I, II, III, respectively)
(P = 0.04). These results are shown in Table 3.
Adverse effects
Hypocalcemia occurred in 2 patients (13.3%) in cal-
citonin group, and in 3 patients (20%) in alendronate
group, which necessitated further calcium carbonate sup-
plementation. All drugs were well tolerated, and clinical
side effects were mild in the form of nausea and epi-
gastric pain in 2 patients (13.3%) in alendronate group,
and nasal stuffiness in 2 patients (13.3%) in calcitonin
group. These side effects were not severe enough to cause
withdrawal from the study. The symptoms decreased and
subsequently disappeared with continuation of the
therapy.
DISCUSSION
The occurrence of bone loss is independent of the or-
gan transplanted and has been frequently diagnosed after
heart, lung, liver, bone marrow, and kidney transplan-
tation [18]. In renal transplant patients, post-transplant
bone loss is more complex [19]. Because osteoporosis
(OP) remains a well-known risk factor for bony fractures,
and, on the other hand, corticosteroids and CsA could not
always be avoided in immunosuppression protocols, spe-
cific antiosteoporotic treatment is necessary to preserve
or restore bone mass. Specific drug treatment includes
supplemental calcium and prescription of antiresorptive
drugs and drugs that exhibit a direct effect on bone forma-
tion. However, the use of different methods of prevention
has not been defined.
After 1 year of treatment with different modali-
ties, 1-hydroxycholecalciferol (alfacalcidol), alendronate,
and calcitonin, there was a consistent improvement in
BMD in the all treatment groups compared to the non-
treated control group. These results are in agreement
with many other studies that could demonstrate sub-
stantial prevention of bone loss after transplantation
[12–14, 21–22, 23–26]. After 1 year of treatment with
1-hydroxycholecalciferol (alfacalcidol), patients in this
group clearly had suppression of iPTH accompanied
by increase of calcium level that may be in consis-
tent with more suppression of persistent hyperparathy-
roidism, which is a known risk factor for bone loss in renal
transplant recipients compared to other organ transplant
recipients [27]. The transplanted kidney begins to synthe-
size calcitriol, often within hours of transplantation, and
this affects parathyroid activity, reducing PTH concen-
tration substantially but never enough to reach normal
levels, so even transplant patients with best outcome in
terms of renal function fail to manifest full suppression
of PTH. Treatment with active vitamin D could result in
suppression of PTH, and with subsequent improvement
of hypophosphatemia [12, 28, 29].
The significant differences in BMD between the treat-
ment groups in favor of the alfacalcidol-treated patients
indicate that long-term treatment with alfacalcidol has
a beneficial effect on the preservation of bone mass in
kidney transplant recipients. Patients in the alfacalcidol
group tended to show a greater increase of BMD at dif-
ferent sites, though not significant from other treatment
except at femur neck. In the appendicular skeleton, treat-
ment with active vitamin D had less effect than axial
skeleton, which is in keeping with others [20], and may be
related to the fact that trabeclular bone (predominantly
present in lumber spine) is more active and responds
faster than cortical bone (mainly present in distal radius).
Indications of a reduction in bone turnover caused by the
alfacalcidol treatment could be implied from the signifi-
cant decrease of the plasma levels of the bone formation
markers, osteocalcin and AP, as well as the substantial
decrease in plasma PTH in the active treatment group.
Our results confirm the significant positive effects of ac-
tive vitamin D on bone loss reported in short-term studies
of nontransplant steroid-treated patients [21], nonrenal
transplant recipients [22], and in renal transplant recipi-
ents [29]. De Sevaux et al [29], using 0.25 lg of 1a-hydroxy
vitamin D and calcium for 6 months on recent renal trans-
plant recipients, reduced bone loss in the lumber spine
and the trochanteric region, and almost completely pre-
vented bone loss in the femoral neck. The beneficial ef-
fects of active vitamin D could be partially explained in
renal transplant recipients due to the unique presence
of secondary hyperparathyroidism and renal osteodys-
trophy in these patients. A mild vitamin D deficiency
might have contributed to the aggravation of secondary
hyperparathyroidism [23]. However, due to possible hy-
percalcemia, it remains unclear whether a higher dose of
alfacalcidol would provide further benefit.
The inhibition of bone resorption by biphosphonates
is effective in glucocorticoid-induced osteoporosis. Ran-
domized trials in renal transplant recipients also demon-
strate benefits [6, 9, 14, 16, 18]. However, few studies to
date address the effectiveness of specific antiresorptive
therapies in preventing bone loss after transplantation.
Fan et al [16] addressed the efficacy of biphosphonates
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to prevent bone loss immediately after transplantation.
However, in another study [20] on osteopenic patients
treated with clodronate after transplantation, an insignif-
icant lumber spine BMD gain of 3% compared with
placebo occurred; however, no effect on femoral neck
BMD was seen. Our results confirm the positive effects
of alendronate on BMD gain at lumber spine, femoral
neck, and forearm. However, there are several limi-
tations regarding the use of biphosphonates to treat
RTx-associated bone disease. Its use in high fracture
risk patients, namely postmenopausal women and those
with diabetes mellitus, with the presence of low turnover
(adynamic-like) bone lesion and the potential nephrotox-
icity, make the use of biphosphonates in renal transplant
recipients questionable.
Bone loss is also attenuated with subcutaneous or in-
tranasal calcitonin [14, 25]. Grotz et al [14] evaluated
the efficacy of calcitonin and clodronate in combination
with calcium compared to control group with supplemen-
tal calcium alone in 46 RTx recipients who had post-
transplant osteopenia, with a significant increase in BMD
at the lumber spine in the 3 groups compared to the basal
values, but with no difference observed between among
the 3 groups. Our finding could demonstrate the efficacy
of intranasal calcitonin in the prevention of bone loss in
recent RTx recipients compared to the control group. We
speculate that early use of calcitonin in RTx recipients
may be more beneficial.
At baseline, parathyroid hormone levels were slightly
increased, indicating only partial remission of secondary
hyperparathyroidism after transplantation. Biochemi-
cal markers of bone formation did not change signifi-
cantly under osteoporosis therapy. Resorption markers
decreased continuously in the long-term follow-up, but
they did not correlate with the increase in BMD. In con-
trast, mean average values were still above the normal
range, indicating continuous enhanced bone resorption
in a considerable number of patients.
Within our study period, iPTH decreased significantly,
although without reaching normal values. Comparable
to several studies in renal transplant recipients, our re-
sults reflect the ability of active vitamin D to control
partially the secondary hypersecretion of iPTH. The
prompt decrease of iPTH after initiating a prevention
therapy, and the increase in BMD within the follow-
ing 12 months in alfacalcidol group supports the role of
iPTH as a key factor of bone loss. We suggest that iPTH
might have been normalized with higher alfacalcidol
group doses, followed by a more pronounced increase in
BMD.
The major limitation of our study is the relatively small
number of patients. A subdivision into only 2 groups
would probably have allowed more statistical power.
However, we intended to exclude women in our study
to decrease the bias caused by gender distribution, and
this exclusion avoided factors such as postmenopausal
osteoporosis. Also, an important point in our study is
that we initiated treatment as early as the first week
after transplantation to exclude the very rapid loss soon
after transplantation, so that the initial rapid bone loss
after transplantation did not superimpose itself on the
preventive treatment effect. A larger trial with fracture
as an end point would be required to assess the benefit
on fracture incidence in this population.
CONCLUSION
Treatment of osteoporosis with alfacalcidol, calcitonin,
and alendronate seems to be effective and secure in kid-
ney transplant recipients. Optimization of osteoporosis
therapy should include active vitamin D to keep the
serum calcium levels, which could avoid aggravation of
persisting hyperparathyroidism.
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